haematology

News in brief: Oral factor XIa inhibitor milvexian in Phase 2 trial; Haematologist numbers for 2021 revealed; Plasma products hit by pandemic restrictions

Oral factor XIa inhibitor milvexian in Phase 2 trial Factor XI inhibition with oral milvexian has been shown to reduce the risk of postoperative VTE without increasing the risk of bleeding. An international phase 2 trial across 18 countries including Australia compared milvexian (25, 50, 100, 200 mg twice daily or 25, 50, 200 mg ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic